読み込み中
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
前日終値
$9.05
+$0.04 · +0.44%
日中の時刻はETです。市場データは遅延する場合があります。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日中レンジ
現在 $9.05
52週レンジ
現在 $9.05
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
88
大幅な割安
センチメント
45
まちまち
リスク
45
やや高いリスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日中レンジ
現在 $9.05
52週レンジ
現在 $9.05
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4376.6万 USD | 634.4万 USD | — | — | — |
| 売上原価 | 154.1万 USD | — | — | — | 149.9万 USD |
| 粗利益 | 4222.5万 USD | 634.4万 USD | — | — | −149.9万 USD |
| 研究開発 | 5603.9万 USD | 4121.1万 USD | 5213.6万 USD | 5920.1万 USD | 5118.8万 USD |
| 販売・一般管理 | 2970.9万 USD | 2477.8万 USD | 2699.7万 USD | 2994.8万 USD | 2235.7万 USD |
| 営業費用 | 8420.7万 USD | 6692.6万 USD | 7913.3万 USD | 8914.9万 USD | 7354.5万 USD |
| 受取利息 | 340万 USD | — | — | — | 600 USD |
| 支払利息 | — | 10万 USD | — | — | 60万 USD |
| 減価償却費と償却費 | 154.1万 USD | 164.4万 USD | 190万 USD | 184.7万 USD | 149.9万 USD |
| 営業利益 | −4198.2万 USD | −6058.2万 USD | −7913.3万 USD | −8914.9万 USD | −7504.4万 USD |
| 純利益 | −3503.6万 USD | −5824.1万 USD | −7640.4万 USD | −8822.2万 USD | −7580万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$98.00
上昇余地（982.87%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI127.48万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF49.47万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC10.6万0.01%13.17億 USD0.60%$183+0.11%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.36万0.00%61.81億 USD0.26%$68.28+0.25%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.01万0.00%455.91億 USD0.17%$84.44+0.44%
Dimensional - US Core Equity 2 ETFDFAC2288.540.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
